Expertise in
16
conditions

Dr. George B. Selby

Hematology
Stephenson Cancer Center-Infusion Center
800 NE 10th St, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
44 Years of Experience
Expertise in
16
conditions
Stephenson Cancer Center-Infusion Center
800 NE 10th St, 
Oklahoma City, OK 

Overview

George Selby is a Hematologist practicing medicine in Oklahoma City, Oklahoma. He has been practicing medicine for over 44 years.

Dr. Selby is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 12 clinical trials. Dr. Selby is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OK

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Stephenson Cancer Center-Infusion Center
800 NE 10th St, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 1/Phase 2
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

22 Total Publications

Incidence and risk factors for graft failure in the modern era of cord blood transplantation.
Incidence and risk factors for graft failure in the modern era of cord blood transplantation.
Journal: Vox sanguinis
Published: April 04, 2022
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sami Ibrahimi is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Ibrahimi is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ibrahimi is currently accepting new patients.

Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Asch is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Asch is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Asch is currently accepting new patients.

Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Referral may be required

SSM Health Cancer Care

1000 N. Lee Ave., 
Oklahoma City, OK 
 (1.4 miles away)
405-228-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Board certified in medical oncology, Todd Kliewer, MD is a physician in the Frank C. Love Cancer Institute at SSM Health St. Anthony Hospital - Oklahoma City and SSM Health Cancer Care in Midwest City. He treats patients in two convenient locations in Midtown Oklahoma City and Midwest City. Dr. Kliewer is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Breast Cancer. Dr. Kliewer is board certified in Oklahoma State Board Of Medical Licensure & Supervision, American Board Of Internal Medicine/Medical Oncology , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Kliewer is currently accepting new patients.

Frequently Asked Questions about Dr. George B. Selby

How do I make an appointment with Dr. George B. Selby?

You can book an appointment with Dr. George B. Selby by calling their office at 405-271-4022. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. George B. Selby a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. George B. Selby is classified as an Distinguished expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. George B. Selby specialize in?

While Dr. George B. Selby is a Hematology, they have specific expertise in Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. George B. Selby participate in research or clinical trials?

Yes. Dr. George B. Selby has published 22 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Dr. George B. Selby's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. George B. Selby accept my insurance?

Dr. George B. Selby accepts most major insurance plans, including Aetna and Health Care Services Corporation. We recommend calling the office directly at 405-271-4022 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Selby's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile